Alto Neuroscience missed the primary endpoint for a study of its ALTO-101 drug for the treatment of cognitive impairment associated with schizophrenia.

Can living neurons replace AI? A new study shows that biological neural networks (BNNs) can be trained to perform reservoir ...

Why is AI overconfident? A new study explores "internal embodiment," the missing link in AI safety. Researchers explain how a ...

Indianapolis-based Eli Lilly and Co. announced plans to acquire UK-based Centessa Pharmaceuticals in a deal worth up to $7.8 ...

In a landmark decision, a Los Angeles jury has found that social media company Meta and video streaming service YouTube ...

Social media apps like Instagram have drawn criticism for allegedly harming users’ mental health, but could an app on your phone actually train your brain to be happier? That’s the idea behind Matter ...

In a powerful demonstration of financial strength and strategic foresight, Eli Lilly and Company (NYSE: LLY) recently committed over $10 billion to two major initiatives in just a matter of days.

The expert has published a new book ‘Without Noise’ that helps people to silence your mind “to think and choose better.” ...

In recent years, the integration of neuroscience principles into business practices has gained significant attention due to its remarkable results. For example, companies that adopt neuroscience-based ...

Gen Z is picking up pay phones to call strangers from another generation. Here’s how the experiment works — and why it matters.